Barter

Real Chemistry Expands European Presence

Retrieved on: 
Thursday, November 9, 2023
Technology, Social Media, Health, Blogging, Consulting, Professional Services, Artificial Intelligence, Other Communications, Publishing, Public Relations, Investor Relations, Marketing, Advertising, General Health, Communications, AstraZeneca, Havas, Economics, MBA, Research, Multimedia, Digital, Real Chemistry, Trustee, Real, Barter, Neuroscience, Apple, ESSEC Business School, GSK, Biochemistry, Chemistry, Bloomberg, Tesco, Indian Telly Awards, Parmentier, PRWeek, Patient, Doctor of Philosophy, D, Management, Nursing, Merck, UPF

Real Chemistry, the leading provider of AI-driven insights and marketing and communications for the healthcare industry, today announced the expansion of its European presence with the addition of four new leaders and the opening of a second UK-based office in Manchester.

Key Points: 
  • Real Chemistry, the leading provider of AI-driven insights and marketing and communications for the healthcare industry, today announced the expansion of its European presence with the addition of four new leaders and the opening of a second UK-based office in Manchester.
  • View the full release here: https://www.businesswire.com/news/home/20231108680766/en/
    “We have had tremendous growth in the EMEA market since opening our London office in 2009,” said Shankar Narayanan, CEO of Real Chemistry.
  • These four senior leaders join Real Chemistry on the heels of the firm’s streak of award wins for its European and U.S. work.
  • Expanding our presence in Europe gives our clients increased global expertise and additional medical, scientific and advertising leadership.”

New Relic Announces David Barter as Chief Financial Officer

Retrieved on: 
Thursday, August 4, 2022
Software, Technology, Other Technology, Adidas Runtastic, Barter, Philosophy, WFS, Industry, NYSE, Guidewire Software, CFO, Ryanair, World Fuel Services, Growth, SEC, Board, Achievement, Microsoft, Analysis, Form 10-K, Master of Engineering Management, Financial condition report, Engineering, Business administration, Board of directors, University of Notre Dame, Goal, Model N, University, American Red Cross, General Electric, IPO, Result, Master of Business Administration, Topgolf, Management, New Relic, Australia Post, Chegg

New Relic (NYSE: NEWR), the observability company, announced David Barter as the companys next Chief Financial Officer.

Key Points: 
  • New Relic (NYSE: NEWR), the observability company, announced David Barter as the companys next Chief Financial Officer.
  • Barter brings nearly three decades of high-growth public and private company finance experience to New Relic.
  • Barter is an established business leader with proven success leading the financial strategies of public companies in the technology sector.
  • I was drawn to New Relic because of its reputation as an industry-leading observability company and its focus on engineers with an innovative platform and business model, said David Barter.

NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe

Retrieved on: 
Tuesday, June 28, 2022
Health, Gastroenterology, Barter, Practitioner, Covington & Burling, Patient, Research and development, Ford Motor Company, Research, Probability, CVD, LLP, Total, Alzheimer's disease, Growth, TULIP, Company, Goal, Hyperlipidemia, ROSE, Inflammation, Development, Infection, Cardiology, Dyslipidemia, Ezetimibe, Lists of diseases, AHA, Diet, Ascendant, Standard of care, Cardiovascular disease, P, Quality of life, Elsevier, Degenerative disease, Human, Goldman Sachs, Risk, Analgesic, Vol, Safety, CETP, Forward-looking statement, Pharmaceutical industry, Menarini, COVID-19

MIAMI and FLORENCE, Italy and NAARDEN, Netherlands, June 28, 2022 /PRNewswire/ -- NewAmsterdam Pharma (NewAmsterdam), a clinical-stage company focused on the research and development of transformative oral therapies for major metabolic diseases, and the Menarini Group (Menarini), an Italy-based, privately held, international pharmaceutical company, today announced an exclusive license agreement for the commercialization of obicetrapib, if approved, in Europe, either as a monotherapy or as part of a fixed dose combination with ezetimibe, for cardiovascular diseases. Obicetrapib is NewAmsterdam's next-generation oral, low-dose and once-daily cholesteryl ester transfer protein (CETP) inhibitor therapeutic candidate, for which a promising safety and efficacy profile as an LDL-lowering adjunct to maximally tolerated statin therapy in patients with dyslipidemia has been observed through Phase 2b trials. Under the collaboration agreement, NewAmsterdam will retain all rights to commercialize obicetrapib, if approved, in the rest of the world, as well as rights to develop certain forms of obicetrapib for other diseases such as Alzheimer's disease.

Key Points: 
  • "We are delighted to enter into this agreement with Menarini," said Michael Davidson, M.D., chief executive officer of NewAmsterdam Pharma.
  • NewAmsterdam will be eligible to receive up to 863 million in potential clinical, regulatory and commercial milestones, bringing the total potential deal value to 1,005.5 million.
  • In addition, Menarini will pay NewAmsterdam tiered double-digit percentage royalties from the teens to mid-twenties on net sales of obicetrapib in Europe.
  • Moelis & Company LLC is acting as financial advisor and Covington & Burling LLP is acting as legal advisor to NewAmsterdam Pharma.

NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe

Retrieved on: 
Tuesday, June 28, 2022
Health, Gastroenterology, Barter, Practitioner, Covington & Burling, Patient, Research and development, Ford Motor Company, Research, Probability, CVD, LLP, Total, Alzheimer's disease, Growth, TULIP, Company, Goal, Hyperlipidemia, ROSE, Inflammation, Development, Infection, Cardiology, Dyslipidemia, Ezetimibe, Lists of diseases, AHA, Diet, Ascendant, Standard of care, Cardiovascular disease, P, Quality of life, Elsevier, Degenerative disease, Human, Goldman Sachs, Risk, Analgesic, Vol, Safety, CETP, Forward-looking statement, Pharmaceutical industry, Menarini, COVID-19

MIAMI and FLORENCE, Italy and NAARDEN, Netherlands, , June 28, 2022 /PRNewswire/ -- NewAmsterdam Pharma (NewAmsterdam), a clinical-stage company focused on the research and development of transformative oral therapies for major metabolic diseases, and the Menarini Group (Menarini), an Italy-based, privately held, international pharmaceutical company, today announced an exclusive license agreement for the commercialization of obicetrapib, if approved, in Europe, either as a monotherapy or as part of a fixed dose combination with ezetimibe, for cardiovascular diseases. Obicetrapib is NewAmsterdam's next-generation oral, low-dose and once-daily cholesteryl ester transfer protein (CETP) inhibitor therapeutic candidate, for which a promising safety and efficacy profile as an LDL-lowering adjunct to maximally tolerated statin therapy in patients with dyslipidemia has been observed through Phase 2b trials. Under the collaboration agreement, NewAmsterdam will retain all rights to commercialize obicetrapib, if approved, in the rest of the world, as well as rights to develop certain forms of obicetrapib for other diseases such as Alzheimer's disease.

Key Points: 
  • "We are delighted to enter into this agreement with Menarini," said Michael Davidson, M.D., chief executive officer of NewAmsterdam Pharma.
  • NewAmsterdam will be eligible to receive up to 863 million in potential clinical, regulatory and commercial milestones, bringing the total potential deal value to 1,005.5 million.
  • In addition, Menarini will pay NewAmsterdam tiered double-digit percentage royalties from the teens to mid-twenties on net sales of obicetrapib in Europe.
  • Moelis & Company LLC is acting as financial advisor and Covington & Burling LLP is acting as legal advisor to NewAmsterdam Pharma.

NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal to Commercialize Obicetrapib in Europe

Retrieved on: 
Tuesday, June 28, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Health, Gastroenterology, Barter, Practitioner, Covington & Burling, Patient, Research and development, Ford Motor Company, Research, Probability, CVD, LLP, Â, Growth, TULIP, Company, Multimedia, Goal, Hyperlipidemia, ROSE, Inflammation, Development, Infection, Cardiology, Dyslipidemia, Ezetimibe, Lists of diseases, AHA, Diet, Ascendant, Standard of care, Cardiovascular disease, P, Elsevier, Degenerative disease, Quality of life, Human, Goldman Sachs, Risk, Analgesic, Vol, Safety, CETP, Forward-looking statement, Pharmaceutical industry, Menarini, COVID-19

View the full release here: https://www.businesswire.com/news/home/20220628005053/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220628005053/en/
    We are delighted to enter into this agreement with Menarini, said Michael Davidson, M.D., Chief Executive Officer of NewAmsterdam Pharma.
  • Obicetrapib, if approved, could radically alter the treatment landscape in cardiovascular disease by providing an effective and oral option for hyperlipidemia patients in Europe said Elcin Barker Ergun, Chief Executive Officer of the Menarini Group.
  • In addition, Menarini will pay NewAmsterdam tiered double-digit percentage royalties from the teens to mid-twenties on net sales of obicetrapib in Europe.
  • Moelis & Company LLC is acting as financial advisor and Covington & Burling LLP is acting as legal advisor to NewAmsterdam Pharma.

NewAmsterdam Pharma to Present at Upcoming Medical Conferences New Post-Hoc Analyses from Phase 2 ROSE Trial of Obicetrapib in Patients with Dyslipidemia

Retrieved on: 
Thursday, May 19, 2022
Health, Clinical Trials, General Health, Pharmaceutical, Cardiology, Biotechnology, CEST, Cardiovascular disease, Ezetimibe, High, Barter, LDL, TULIP, NLA, Goal, Health, CVD, Clinical trial, Lists of diseases, Imperial College London, Lipid-lowering agent, Coruscant, Research, Vol, Ascendant, Elsevier, EAS, Diet, Congress, Safety, Apolipoprotein, Public health, Standard of care, AHA, CETP, Ford Motor Company, ROSE, Rose trial grounds, Pharmaceutical industry, Communications satellite, Patient

ROSE (NCT04753606) was designed as a placebo-controlled, double-blind, randomized, Phase 2b dose-finding study to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to high-intensity statin therapy.

Key Points: 
  • ROSE (NCT04753606) was designed as a placebo-controlled, double-blind, randomized, Phase 2b dose-finding study to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to high-intensity statin therapy.
  • A total of 120 patients were randomized to placebo, 5 mg obicetrapib or 10 mg obicetrapib for an 8-week treatment period.
  • Currently, Obicetrapib is being tested in two Phase 3 trials, BROADWAY and PREVAIL, and a secondary Phase 2 trial, ROSE2.
  • Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial.

New Meta-Analysis in European Heart Journal’s Cardiovascular Pharmacotherapy Examines Cholesterol Ester Transfer Protein (CETP) Inhibitors’ Role in Reduction of Diabetes Risk

Retrieved on: 
Wednesday, May 11, 2022
Science, Cardiology, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Standard of care, ROSE, Department, Ford Motor Company, Diet, University, Vol, Health, CVD, Meta-analysis, Roy Taylor (scientist), Ascendant, TULIP, Cardiovascular disease, European Heart Journal, University of Texas Southwestern Medical Center, Patient, Apolipoprotein, Diabetes, Barter, University of Oxford, Internal medicine, Elsevier, CETP, Goal, Research, Lists of diseases, AHA, Risk, Pharmaceutical industry

The analysis examines the effect CETP inhibitors have on reducing new-onset diabetes and related glycemic measures in patients.

Key Points: 
  • The analysis examines the effect CETP inhibitors have on reducing new-onset diabetes and related glycemic measures in patients.
  • In four randomized trials, CETP inhibitors significantly decreased the risk of new-onset diabetes by 16%, with low between-trial heterogeneity.
  • CETP inhibitors also significantly improved or demonstrated a trend towards improvement in glycemic measures in those with and without diabetes.
  • The studies reviewed in this analysis demonstrated risk reduction in new-onset diabetes, highlighting another potential benefit of obicetrapib.

NewAmsterdam Pharma Doses First Patient in Phase 2 Trial of Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy

Retrieved on: 
Tuesday, April 5, 2022
Health, Clinical Trials, Research, Science, Pharmaceutical, Cardiology, Biotechnology, Cholesterol, Apolipoprotein, Absorption, AHA, Vol, LDL, Barter, CVD, Research, Ezetimibe, TULIP, Program, ROSE, Standard of care, Patient, Cardiovascular disease, American Heart, Elsevier, Participation, Health, Safety, Goal, CETP, Lists of diseases, Ascendant, Ford Motor Company, NAP, Pharmaceutical industry, Copper, OBICETRAPIB, NEWAMSTERDAM PHARMA

ROSE2 is a placebo-controlled, double-blind, randomized, Phase 2 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg in combination with ezetimibe 10 mg and as monotherapy, in each case as an adjunct to high-intensity statin therapy.

Key Points: 
  • ROSE2 is a placebo-controlled, double-blind, randomized, Phase 2 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg in combination with ezetimibe 10 mg and as monotherapy, in each case as an adjunct to high-intensity statin therapy.
  • Participants will be randomized to receive combination therapy (i.e., obicetrapib 10 mg + ezetimibe 10 mg), obicetrapib monotherapy (obicetrapib 10 mg), or placebo.
  • A total of 108 patients will be randomized to placebo, 10 mg obicetrapib monotherapy, or 10mg obicetrapib + 10mg ezetimibe combination therapy, dosed as a once-daily oral treatment for an 84-day treatment period.
  • NewAmsterdam is investigating obicetrapib, a next-generation cholesteryl ester transfer protein (CETP) inhibitor, as the preferred LDL-c-lowering therapy for high-risk cardiovascular disease (CVD) patients.

NewAmsterdam Pharma Doses First Patient in PREVAIL, the Cardiovascular Outcomes Trial of Obicetrapib in Adults with Atherosclerotic Cardiovascular Disease (ASCVD)

Retrieved on: 
Tuesday, March 1, 2022
Research, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Janus, Risk, Ascendant, Mortality, Monash University, Diabetes, ROSE, NAP, Company, CETP, Moyamoya disease, Apolipoprotein B, TULIP, Vol, Kaiser Permanente, Lists of diseases, MACE, Patient, Medpace, History, Goal, Standard of care, MD, Barter, Research, Elsevier, Health, Ford Motor Company, Pharmaceutical industry, Amgen, Obicetrapib, NewAmsterdam Pharma, OBICETRAPIB, NEWAMSTERDAM PHARMA

Todays announcement follows the recent announcement of NewAmsterdam dosing the first patient in its BROADWAY trial, Phase 3 study of obicetrapibs LDL-c lowering efficacy.

Key Points: 
  • Todays announcement follows the recent announcement of NewAmsterdam dosing the first patient in its BROADWAY trial, Phase 3 study of obicetrapibs LDL-c lowering efficacy.
  • Over 100 million individuals globally are not achieving their LDL-c goals despite currently available lipid lowering therapies.
  • With PREVAIL we aim to demonstrate the impact that obicetrapibs LDL-c lowering efficacy can provide on patient outcomes in order to help individuals live longer, healthier lives.
  • We are thrilled NewAmsterdam will be positioned to share cardiovascular outcomes data just two years after we expect to release our Phase 3 BROADWAY lipid lowering data.

Bartercard Europe Announces Launch of Licensee Operations Across Europe

Retrieved on: 
Tuesday, May 4, 2021
Articles, Economy, Trade, Economic systems, Pricing, Simple living, Bartercard, Barter, Countertrade, Currency

b'LISBON, Portugal, May 4, 2021 /PRNewswire-PRWeb/ -- At a time when many thousands of small and medium enterprises across Europe are fighting for their survival, many are turning to barter to increase revenue, mobilize idle capacity, and access a network with which to trade and work together.\nBarter trade, also often referred to as counter trade or reciprocal trade, is a form of exchange between businesses that uses an internal currency for record-keeping purposes which equal to the currency of the economy.

Key Points: 
  • b'LISBON, Portugal, May 4, 2021 /PRNewswire-PRWeb/ -- At a time when many thousands of small and medium enterprises across Europe are fighting for their survival, many are turning to barter to increase revenue, mobilize idle capacity, and access a network with which to trade and work together.\nBarter trade, also often referred to as counter trade or reciprocal trade, is a form of exchange between businesses that uses an internal currency for record-keeping purposes which equal to the currency of the economy.
  • This currency can transact just like other currencies using regular payment terminals, and is legal and is regulated and taxable for trade between businesses in Europe.\nBartercard International, founded in Australia in 1991, has licensees in several countries worldwide, including Australia, United Kingdom, New Zealand, Dubai and Thailand.\nBartercard Continental Europe ( https://bartercard-europe.com ) holds the 40-country Master License for Europe and is in talks with companies, business associations and entrepreneurs in several countries in Europe to launch Bartercard operations in their countries.\nBartercard Europe is headquartered in Lisbon, Portugal, an emerging innovation and technology hub in southern Europe which hosts Europe\'s largest tech conference, the Web Summit, each year.\n"We chose the date of May 1st for our launch as it signifies a time of survival from the winter, of the rebirth of spring, and coming to the rescue of thousands of businesses across Europe that are crying out for help as they fight to survive the economic impacts of the pandemic and the policy responses which have left thousands of businesses closed or idle.
  • We hear them calling out, \'Mayday, Mayday\' and we are responding," says Sergio Lopo, CEO and Managing Director of Bartercard Europe.\nThe management team of Bartercard Europe are all seasoned professionals from different parts of Europe and North America, with backgrounds in trade finance and insurance, in media and communications, and in supporting small and medium enterprises by aggregating them into a scale which gives them access to services that are normally reserved only for large companies.\nAlthough barter companies are not new to Europe, they are much less common here than they are in North America, where there are dozens of companies providing barter exchange services across the continent.\n"As barter companies in Europe arose during the Great Depression, we see them coming again as the economy declines.
  • Barter is counter-cyclical in nature, meaning when the economy goes into decline, businesses start trading their goods and services more directly with each other," Sergio Lopo continued.\n'